Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

T cell vaccine constructed by secretory component of gene engineering-based aAPC (artificial Antigen Presenting Cell) as well as preparation method and application thereof

A technology of genetic engineering and cell secretion, which is applied in the field of preparation of T cell vaccines and can solve the problems of lack of endogenous expression

Inactive Publication Date: 2018-10-02
项雯华
View PDF6 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Because its expression of CD54 and LFA-3 helps to form an effective immune synapse to promote T cell activation [11,12], while its lack of endogenous expression of HLA-A, B and DR molecules limits its allogeneic Side effects caused by T cell stimulation

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • T cell vaccine constructed by secretory component of gene engineering-based aAPC (artificial Antigen Presenting Cell) as well as preparation method and application thereof
  • T cell vaccine constructed by secretory component of gene engineering-based aAPC (artificial Antigen Presenting Cell) as well as preparation method and application thereof
  • T cell vaccine constructed by secretory component of gene engineering-based aAPC (artificial Antigen Presenting Cell) as well as preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0039] The present invention shows that activated non-specific T cells can acquire vesicles derived from genetically engineered artificial antigen-presenting cells, in particular, these cells can acquire antigen-specific histocompatibility complexes and co-stimulatory molecules from the vesicles. The present invention shows that these vesicle-derived molecules are functional. In this way, non-specific T cells targeted by vesicles can directly stimulate antigen-specific immune responses.

[0040] The present invention shows that the genetically engineered artificial antigen-presenting cells are derived from K562 cells that lack endogenously expressed HLA-A, B and DR histocompatibility conformers. K562 cells were first expressed by two eukaryotic expression plasmid vectors pcDNA Hygro / HLA-A2 and

[0041] pcDNA Neo / CD80 transfection. AdV Gag and AdV 41BBL Transfection to form genetically engineered antigen-presenting cells K562 expressing transgenic HLA-A2, CD80, Gag and 41...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Diameteraaaaaaaaaa
Login to View More

Abstract

The invention discloses a secretory component vesica of a gene engineering-based aAPC (artificial Antigen Presenting Cell), as well as preparation and application of a T cell vaccine constructed by anexosome. By transfecting two kinds of eukaryotic expression plasmids of pcDNAHLA-A2 and pcDNACD80 and infecting two kinds of recombinant adenovirus carriers of AdVGag and AdV41BBL, a gene engineering-based K562A2 / Gag / CD80 / 41BBLaAPC is constructed; then exosomes are purified in K562A2 / Gag / CD80 / 41BBL culture supernatant through a differential superspeed centrifugal method, and electron microscopingand immunoblotting analysis can be carried out, wherein the exosomes are in co-incubation with nonspecific T cells of Con-A stimulated HLA-A2 transgenic mice through incubating, so that Gag-Texo vaccine having HLA-A-A2 limitation and Gag specificity is constructed. According to the secretory component vesica disclosed by the invention, the aAPCK562A2 / Gag / CD80 / 41BBL vesica in unlimited source andcontinuous growth is used for replacing a DC vesica in limited source and is used for preparing an HIV-1 (Human Immunodeficiency Viru I) Gag specific T cell vaccine. A novel method for preparing the Tcell vaccine by using the gene engineering-based aAPC has important influence on development of clinic therapeutic vaccines for a patient suffering HIV-1.

Description

technical field [0001] The invention belongs to the field of biomedicine, and in particular relates to a preparation method and application of a T cell vaccine constructed from secretory bodies of genetically engineered artificial antigen-presenting cells. Background technique [0002] Acquired immunodeficiency syndrome (AIDS) in patients infected with human immunodeficiency virus-I (HIV-I) is a rapidly expanding global pandemic disease. Effective antiviral therapy (HAART) can successfully inhibit the replication of the virus and significantly improve the prognosis of patients [1]. However, it did not restore the anti-HIV-1 immune response. Drug treatment during the chronic phase of inflammation does not reverse virus-induced CD4 + T cells and CD8 + Decline of effector T cells, leading to latent HIV-1 virus [2]. Therefore, it is of practical significance to urgently develop new therapeutic strategies to improve virus control during drug intermittent treatment, so that pa...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/00A61K39/12A61P31/20A61P35/00A61P37/06C12N5/0783C12N5/0784
CPCA61K39/0008A61K39/0011A61K39/12A61K2039/5158A61K2039/572C12N5/0636C12N5/0639C12N2740/16034
Inventor 项建华
Owner 项雯华
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com